Healthcare's persistent underperformance over the past two years has been a topic of concern for investors, with political uncertainty, rising interest rates, and the surge in capital towards AI and technology stocks contributing to the sector's struggles. However, beneath the headline weakness, the healthcare sector's fundamentals remain robust across multiple sub-sectors, with underlying earnings quality and revenue growth intact. This presents an opportunity for wealth allocators to re-engage with the sector, particularly at discounted valuations.
One key area of interest is cardiovascular medicine, where lipoprotein(a) (Lp(a)) represents a multi-billion-dollar opportunity. With no approved therapy currently available for this genetically determined cholesterol variant, several companies are in late-stage trials, with data expected in 2026. This presents a compelling investment case, as the market for Lp(a) treatments is expected to be significant.
In medtech, robotic surgery continues to advance, with Intuitive Surgical's Da Vinci 5 system incorporating AI-driven features such as simulated surgical training and tissue pressure sensing. This structural shift is creating new blockbuster markets with durable growth profiles, such as continuous glucose monitoring and soft-tissue surgical robotics.
Artificial intelligence (AI) is emerging as a cost and efficiency lever across drug development, clinical trials, and surgical systems, rather than a disruptive threat to the sector. AI is being deployed to accelerate drug development, improve patient selection for clinical trials, and predict toxicity profiles earlier in the process, with potential savings of USD70 billion in drug development costs by 2028.
Biopharma mergers and acquisitions (M&A) activity is accelerating, with the 20 largest biopharma companies holding more than USD1 trillion in combined financial firepower to address looming patent cliffs. This presents a structural imperative for M&A, as big pharma faces hundreds of billions of dollars in revenue at risk over the next four to six years.
The healthcare sector's defensive qualities and innovation-driven growth make it an increasingly logical complement to concentrated technology positions. Wealth managers and family office professionals are recognizing this, with healthcare remaining structurally underweight in most portfolios. As one multi-family office representative noted, healthcare is one of the best sectors for the current generation due to the domain expertise required.
Bellevue Asset Management, a Swiss specialist manager, is positioning itself as a specialist partner for investors seeking differentiated healthcare exposure. With vehicles covering broad healthcare, medtech, and services, and emerging markets healthcare, the firm is making the case that the current dislocation represents a window that disciplined allocators would do well not to ignore. The current valuations provide an attractive entry point, with the potential for meaningful rerating as the sector's fundamentals continue to improve.
